Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Amide derivatives and nociceptin antagonists

a technology of nociceptin and amide derivatives, applied in the field of nociceptin antagonists, can solve the problems of many unknown parts in the central action mechanism, considered ineffective for visceralgia, etc., and achieve the effect of free of marked side effects

Inactive Publication Date: 2006-02-09
JAPAN TOBACCO INC
View PDF6 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a pharmaceutical agent with a unique mechanism of action for pain relief, particularly sharp pain such as postsurgery pain and pain caused by sensory nerve abnormality. The agent has a selective action on ORL-1 receptor and is safe with minimal side effects. The invention also provides a novel compound with nociceptin antagonistic action. The technical effects of the invention include improved pain relief, reduced side effects, and the development of a new pharmaceutical agent for pain treatment.

Problems solved by technology

Pain caused by injury, surgery, inflammation and the like, as well as chronic pain stemming from injury, dysfunction and the like of nerves after recovery from an injury is one of the major clinical problems.
Other side effects of respiratory suppresion, nausea, emesis, constipation, dysuria and the like restrict their use.
Antipyretic analgesic is effective for superficial pain, such as toothache, myalgia and the like, but is considered to be ineffective for visceralgia.
However, there are many unknown parts in the central action mechanism thereof.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amide derivatives and nociceptin antagonists
  • Amide derivatives and nociceptin antagonists
  • Amide derivatives and nociceptin antagonists

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1-1

Synthesis of 4,6-diamino-2-methylquinoline

[0259] The synthesis was carried out according to a reference publication (Journal of the American Chemical Society, 70, 4065, 1948).

Step 1

[0260] 4-Aminoacetoanilide (150.2 g, 1 mol) was added to a solution of methyl acetoacetate (136.8 g, 1.1 mol) in methanol (450 ml) and the mixture was refluxed under heating for 17 hours. The reaction vessel was cooled to 0° C. and the resulting white precipitate was collected by filtration to give methyl β-(p-acetamidophenylamino)crotonate (231.5 g, 93%, white crystals).

Step 2

[0261] Methyl β-(p-acetamidophenylamino)crotonate (231.5 g, 0.93 mol) obtained in Preparation Example 1-1, Step 1 was added by small portions to Dowtherm A (trademark, 600 ml) which underwent refluxing under heating. The mixture was refluxed under heating for 10 minutes and the reaction mixture was cooled to room temperature. The resulting precipitate was collected by filtration and washed with ethyl acetate. The obtained cru...

preparation example 1-2

Synthesis of 4,6-diamino-2-methylquinoline

Step 1

[0264] To 5-nitroisatin (19.21 g, 0.1 mol) were added acetone (36.7 ml, 0.5 mol) and aqueous ammonia (100 ml) and the mixture was heated in an autoclave at 100° C. for 12 hr. The reaction mixture was cooled to room temperature and the resulting crystals were collected by filtration and washed with water. The obtained crystals were dried by heating under reduced pressure to give 2-methyl-6-nitroquinoline-4-carboxamide (18.30 g, 79%).

Step 2

[0265] To 2-methyl-6-nitroquinoline-4-carboxamide (231 mg, 1 mmol) obtained in Preparation Example 1-2, Step 1 was added an aqueous sodium hypochlorite solution (0.851 ml,1.2 mmol) and the mixture was stirred at 0° C. for 2.5 hr. The reaction mixture was added dropwise to hot water (10 ml) under reflux with heating and the mixture was refluxed under heating for 20 min. The reaction mixture was cooled to room temperature and the resulting crystals were collected by filtration and dried by heating ...

preparation example 1-3

Synthesis of 6-amino-2-methyl-4-methylaminoquinoline

Step 1

[0267] N-(4-Hydroxy-2-methyl-6-quinolyl)acetamide (4.32 g, 20 mmol) and phosphorus oxychloride (9.32 ml, 100 mmol) were heated at 100° C. for 15 min. The reaction mixture was cooled to room temperature and poured into ice water. Thereto was added 28% aqueous ammonia to make the solution alkaline. The resulting insoluble matter was collected by filtration, washed with ether and water, dried under reduced pressure at 80° C. to give N-(4-chloro-2-methyl-6-quinolyl)acetamide (6.85 g, crude, yellow solid).

Step 2

[0268] A suspension of N-(4-chloro-2-methyl-6-quinolyl)acetamide (4.0 g, crude) obtained in Preparation Example 1-3, Step 1 and 85% potassium hydroxide (6.6 g, 100 mmol) in N-methylformamide (100 ml) was heated at 170° C. for 3 hr 20 min. The reaction mixture was cooled to room temperature and the reaction mixture was diluted with chloroform and water. The chloroform layer was washed successively with saturated aqueou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a compound of the formula [1′]wherein R2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, —O—, —S— and the like, ring G is aryl, heterocyclic group and the like, R5 is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R5 may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1′] as an active ingredient. The compound [1′] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1′] as a nociceptin antagonist or analgesic.

Description

TECHNICAL FIELD [0001] The present invention relates to a nociceptin antagonist containing a novel amide derivative or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to an analgesic containing,-as an active ingredient, a novel amide derivative or a pharmaceutically acceptable salt thereof, which show analgesic effect as nociceptin antagonist by selectively acting on an opioid receptor like-1 receptor and which are useful for the treatment of pain, particularly sharp pain or pain caused by sensory nerve abnormality, such as hyperalgesia and allodynia. The present invention moreover relates to a novel use of a certain kind of amide derivative as a nociceptin antagonist and analgesic. BACKGROUND ART [0002] Pain is a sensation felt by anybody and is an important vital signal or alarm signal. [0003] Pain caused by injury, surgery, inflammation and the like, as well as chronic pain stemming from injury, dysfunction and the like of nerves after...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/473A61K31/498A61K31/47A61K31/4184A61K31/166A61P29/00C07C235/42C07D215/12C07D215/38C07D215/42C07D217/22C07D219/12C07D221/16C07D235/28C07D401/12C07D405/12C07D409/12C07D413/12
CPCA61K31/4184C07D413/12A61K31/473A61K31/498C07C235/42C07D215/38C07D215/42C07D217/22C07D219/12C07D221/16C07D235/28C07D401/12C07D405/12C07D409/12A61K31/47A61P23/00A61P29/00A61K31/5585
Inventor SHINKAI, HISASHIITO, TAKAOYAMADA, HIDEKI
Owner JAPAN TOBACCO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com